SEC Form 4 · accession 0001450324-18-000008
AIM ImmunoTech Inc. · AIM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas K. Equels
Officer — Exec. Vice Chairman/CEO/Pres. · Director
Period of report
Nov 30, 2018
Accepted (ET)
Dec 3, 2018 · 11:32 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000946644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 30, 2018 | P | 1,354 | $0.1891 | A | 779,661 | D | |
| Common Stock | Nov 30, 2018 | P | 5 | $0.1892 | A | 779,666 | D | |
| Common Stock | Nov 30, 2018 | P | 9,557 | $0.19 | A | 789,223 | D | |
| Common Stock | Nov 30, 2018 | P | 2,400 | $0.193 | A | 791,623 | D | |
| Common Stock | Nov 30, 2018 | P | 50 | $0.1938 | A | 791,673 | D | |
| Common Stock | Nov 30, 2018 | P | 300 | $0.1944 | A | 791,973 | D | |
| Common Stock | Nov 30, 2018 | P | 334 | $0.1945 | A | 792,307 | D | |
| Common Stock | Nov 30, 2018 | P | 6,000 | $0.196 | A | 798,307 | D |
Table II — derivative securities
No Table II lines on this filing.